The Tumor Cell Biology [TCB] Study Section reviews applications that focus on mechanisms of tumor cell metabolism and signal transduction that regulate or influence tumor phenotype, behavior, progression, and tumor-associated cachexia. Metabolic and signaling processes considered include those mediated by kinases, phosphatases, redox chemistry, growth factors/growth factor receptors, and nuclear receptors. Emphasis is on tumor/tumor cell intrinsic processes as revealed by in vitro and in vivo studies.
The List of Reviewers lists all present, whether permanent or temporary, to provide the full scope of expertise present on that date. Lists are posted 30 days before the meeting and are tentative, pending any last minute changes.
The membership panel is a list of chartered members only.
- Tumor metabolism: Characterization, mechanisms, regulation, and consequences of tumor cell metabolism including oncogenic metabolic adaptations and therapeutic vulnerabilities
- Autophagy as related to tumor cell metabolism and adaptation
- Signaling pathways mediated by kinases and phosphatases and other molecules including growth factors/receptors, nuclear factors, tumor suppressors and hormonal factors in relation to tumor cell biology, phenotype and behavior
- Redox biology in the regulation of tumor cell signaling and phenotype
- Cachexia as a consequence or reflection of tumor cell metabolism and signaling processes
- Molecular analysis of the composition and function of signaling molecule complexes and their interactions with different signaling pathways in tumors and tumor cells
Shared Interests and Overlaps
There are shared interests between TCB and Tumor Progression and Metastasis (TPM), Tumor Microenvironment (TME), Molecular Oncogenesis (MONC) in signal transduction and tumor cell metabolism. Grant applications that focus on regulation and adaptions of these processes in cancer cells and tumors may be assigned to TCB. Applications that emphasize the effects of these pathways on tumor cell migration, invasion and metastasis may be assigned to TPM. Applications with signaling or metabolic components whose primary focus is on intercellular interactions may be assigned to TME. Applications that focus on early events of oncogenesis may be assigned to MONC.
TCB and Cancer Molecular Pathobiology (CAMP) share interests in autophagy, tumor suppressors, and stress pathways (redox, endoplasmic reticulum, mitochondria). Applications that focus on mechanisms by which these processes affect tumor metabolism and signal transduction may be assigned to TCB. Applications that focus on metabolic stress-induced gene regulation and tumor cell death may be assigned to CAMP.
There are shared interests between TCB and Mechanisms of Cancer Therapeutics-1 (MCT1) in cancer therapeutics, signal transduction mechanisms in cancer cells and tumor metabolism. Applications that use anti-cancer drugs to investigate basic mechanisms of signal transduction or tumor metabolism may be assigned to TCB. Applications that focus on the mechanisms of cancer drug action or drug resistance may be assigned to MCT1.
There are shared interests between TCB and Mechanisms of Cancer Therapeutics 2 (MCT2) in cancer therapeutics and cancer cell signaling and metabolism. Applications that use anti-neoplastic agents to study basic mechanisms of cancer signaling and metabolism may be assigned to TCB. Applications with a primary focus on therapeutic targeting, especially in a translational setting, may be assigned to MCT2.
There are shared interests between TCB and Cellular Signaling and Regulatory Systems (CSRS) in cell signaling and its regulation. Applications that focus on cell signaling mechanisms in the regulation and phenotype of cancer cells may be assigned to TCB. Applications that use cancer cells as a model to understand basic signaling mechanisms may be assigned to CSRS.